Urinary morbidity following ultrasound-guided transperineal prostate seed implantation

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 1, 1999, Pages 59-67

  Gelblum, Daphna Y ^a   Potters, Louis ^a   Ashley, Richard ^b   Waldbaum, Robert ^c   Wang, Xiao Hong ^a   Leibel, Steven ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Mercy Medical Center   (United States)

^c University Medical College   (United States)

Author keywords

Iodine; Palladium; Prostate implant; Urinary morbidity

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; IODINE 125; PALLADIUM; PHENAZOPYRIDINE;

ADULT; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CYSTOSCOPY; DYSURIA; ECHOGRAPHY; HUMAN; IMPLANT; INDWELLING CATHETER; INTERSTITIAL RADIATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NOCTURIA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; SCORING SYSTEM; STRESS INCONTINENCE; TRANSURETHRAL RESECTION; URINARY TRACT OBSTRUCTION;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BRACHYTHERAPY; FOLLOW-UP STUDIES; HEMATURIA; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; ULTRASONOGRAPHY, INTERVENTIONAL; URINATION DISORDERS;

EID: 0032777087     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00176-5     Document Type: Article

References (32)

1. Middleton R.G., Thompson I.M., Austenfeld M.S., et al. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol. 154:1995;2144-2148.
2. Prestidge B.R. Radioisotopic implantation for carcinoma of the prostate Does it work better than it used to? Semin Radiat Oncol. 8:1998;124-131.
3. Pollack A., Zagars G.K. External beam radiotherapy for stage T1/T2 prostate cancer How does it stack up? Urology. 51:1998;258-264.
4. Kupelian P., Katcher J., Levin H., et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores . Cancer J Sci Am. 3:1997;78-87.
5. Eastham J.A., Kattan M.W., Groshen S., et al. Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol. 15:1997;3214-3222.
6. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
7. Ragde H., Elgamal A.A., Snow P.B., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 83:1998;989-1001.
8. Fowler J.E. Jr. Complications of treatment for localized prostate cancer. J Urol. 160:1998;1386.
9. Klein E.A. Comparison of prostate cancer treatments. (letter; comment) Cancer J Sci Am. 3:1997;255.
10. Schultheiss T.E., Lee W.R., Hunt M.A., et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;3-11.
11. Crook J., Esche B., Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function The patient's perspective . Urology. 47:1996;387-394.
12. Lawton C.A., Won M., Pilepich M.V., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate Analysis of RTOG studies 7506 and 7706 . Int J Radiat Oncol Biol Phys. 21:1991;935-939.
13. Nag S., Scaperoth D.D., Badalament R., et al. Transperineal palladium 103 prostate brachytherapy Analysis of morbidity and seed migration . Urology. 45:1995;87-92.
14. Kleinberg L., Wallner K., Roy J., et al. Treatment-related symptoms during the first year following transperineal 1251 prostate implantation. Int J Radiat Oncol Biol Phys. 28:1994;985-990.
15. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 160:1998;1379-1382.
16. Fleming I.D., Cooper J.S., Henson D.E., et al. AJCC cancer staging manual. 5th ed. 1997;Lippincott-Raven, Philadelphia.
17. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate Morbidity and complications . Scand J Urol Nephrol Suppl. 137:1991;113-118.
18. Dattoli M., Wallner K., Sorace R., et al. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 35:1996;875-879.
19. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 32:1995;219-225.
20. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine . Med Phys. 22:1995;209-234.
21. Desai J., Stock R.G., Stone N.N., et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Invest. 6:1998;135-141.
22. Arterbery V.E., Wallner K., Roy J., et al. Short-term morbidity from CT-planned transperineal I-125 prostate implants. Int J Radiat Oncol Biol Phys. 25:1993;661-667.
23. Kawachi I., Barry M.J., Giovannucci E., et al. The impact of different therapies on symptoms of benign prostatic hyperplasia A prospective study . Clin Ther. 18:1996;1118-1127.
24. Barry M.J., Fowler F.J. Jr, Bin L., et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol. 157:1997;10-14.
25. Kaplan S.A., Olsson C.A., Te A.E. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms At 2 years of followup, does it work? J Urol. 155:1996;1971-1974.
26. Barry M.J., Fowler F.J. Jr, Bin L., et al. A nationwide survey of practicing urologists Current management of benign prostatic hyperplasia and clinically localized prostate cancer . J Urol. 158:1997;488-491.
27. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride Meta-analysis of randomized clinical trials . Urology. 48:1996;398-405.
28. Lepor H., Williford W.O., Barry M.J., et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol. 160:1998;1358-1367.
29. Blasko J.C., Ragde H., Grimm P.D., et al. Prostate brachytherapy Importance of technique . J Clin Oncol. 14:1996;1965-1967.
30. Hu K., Wallner K. Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 40:1998;783-786.
31. Roy J.N., Anderson L.L., Wallner K.E., et al. Tumor control probability for permanent implants in prostate. Radiother Oncol. 28:1993;72-75.
32. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 32:1995;465-471.